Aspira Women's Health Inc. Stock price

Equities

AWH

US04537Y2081

Biotechnology & Medical Research

Delayed Nasdaq 12:50:29 2024-03-28 pm EDT 5-day change 1st Jan Change
3.225 USD -5.98% Intraday chart for Aspira Women's Health Inc. -10.66% -20.96%
Sales 2023 * 9.58M Sales 2024 * 14.2M Capitalization 40.16M
Net income 2023 * -17M Net income 2024 * -16M EV / Sales 2023 * 4.19 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 2.83 x
P/E ratio 2023 *
-1.79 x
P/E ratio 2024 *
-2.46 x
Employees 85
Yield 2023 *
-
Yield 2024 *
-
Free-Float 57.54%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Aspira Women's Health Inc.

1 day-2.00%
1 week-1.29%
Current month-13.16%
1 month-15.31%
3 months-9.02%
6 months-36.83%
Current year-15.93%
More quotes
1 week
3.30
Extreme 3.3
3.75
1 month
3.26
Extreme 3.26
4.29
Current year
3.26
Extreme 3.26
5.65
1 year
2.31
Extreme 2.3087
6.75
3 years
2.31
Extreme 2.3087
109.50
5 years
2.31
Extreme 2.3087
158.10
10 years
2.31
Extreme 2.3087
158.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-02-21
Director of Finance/CFO 55 23-06-14
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 23-05-08
Director/Board Member 60 23-05-08
Chairman - 23-05-08
More insiders
Date Price Change Volume
24-03-28 3.225 -5.98% 10 556
24-03-27 3.43 -2.00% 24,759
24-03-26 3.5 -1.69% 21,458
24-03-25 3.56 -2.47% 19,172
24-03-22 3.65 +1.11% 14,010

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Aspira Women's Health Inc. is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Its products include Ova1, Overa, Ova1Plus and OvaWatch. Ova1 is a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy. Overa is a biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity. Ova1Plus is a reflex offering, which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results. OvaWatch is a lab developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass. The Company's products are distributed through its own national sales force, through its decentralized testing platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.43 USD
Average target price
5.6 USD
Spread / Average Target
+63.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Aspira Women's Health Inc. - Nasdaq